The drug will be funded on the NHS to treat hyperkalaemia
News
ViiV submits dispersible form of dolutegravir in the US, EU
The company is seeking approval to market the formulation for children with HIV
CR UK research backs liquid biopsy for breast cancer
Blood tests can provide a bigger, faster picture of mutations present within multiple tumours, the researchers say
Novartis’ Kisqali bests AZ’ Faslodex in breast cancer trial
Adding Kisquali to Faslodex resulted in an almost 30% reduction in risk of death compared to Faslodex alone
UK researchers make new Alzheimer’s disease discovery
Scientists hope the discovery will lead to new treatments for the disease
EU approves new osteoporosis treatment
Amgen and UCB’s Evenity has been given the green light for postmenopausal women with severe osteoporosis to help prevent further fractures
Boris Johnson remains UK prime minister
Conservatives win a huge majority after a crushing defeat for Labour
AZ, Daiichi’s targeted breast cancer therapy on target
Patients achieved a disease control rate of 97.3%
Lilly launches first of its kind trial for RET fusion-positive NSCLC
Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms
Health officials urge public to get flu jabs
Public Health England and NHS England warn flu can be serious and fatal in at-risk groups
Kite files second CAR-T therapy with US regulators
A submission in the EU is expected early next year
Raleigh confirmed as host city for CROY 2020
PharmaTimes are excited to announce that Raleigh, North Carolina has been confirmed as the host city for the 2020 Clinical Researcher of the Year – The Americas competition.
Bird flu outbreak confirmed in Suffolk
Officials have confirmed an outbreak of bird flu in Suffolk, but stress the risk to the public is low
More good news for Janssen’s Darzalex
The drug has hit survival and disease progression targets in Phase III trials
EU expands scope of Vertex’ Kalydeco
Children with cystic fibrosis as young as six months with certain mutations can now access the treatment
